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A b s t r a c t  Twelve children with documented Prader-Labhart-Willi syndrome were treated 
with human growth hormone (24 U/mZ/week) during 1 year. The children were divided 
into three groups: group 1: overweight and prepubertal (n = 6, age 3.8 7.0 years); group 
2: underweight and prepubertal (n = 3, age 0.6-4.1 years); group 3: pubertal (n = 3, age 
9.2-14.6 years). In group 1, height increased from -1.7 SD to -0.6 SD, while weight 
decreased from 1.1 SD to 0.4 SD, with a dramatic drop in weight for height from 3.8 SD 
to 1.2 SD. Hand length increased from -1.5 SD to -0.4 SD and foot length from -2.5 SD 
to -1.4 SD. Body fat, measured by dual X-ray energy absorptiometry, dropped by a 
third, whereas muscle mass increased by a fourth. Physical capability (Wingate test) 
improved considerably. The children were reported to be much more active and capable. 
In group 2, similar changes were seen, but weight for height increased, probably because 
muscle mass increase exceeded fat mass decrease. Changes in group 3 were similar as in 
group 1, even though far less distinct. 
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Introduction 
Prader-Labhart-Willi syndrome (PWS) is caused by lack 
of a specific part of the paternal homologue of chro- 
mosome 15 long arm due to a deletion [14] or a maternal 
uniparental disomy [19, 22]. It was first described in 1956 
[20] and is the most common syndromal cause of marked 
obesity. Its incidence is estimated at 1 in 16.000 live 
births [5]. The characteristic features up to infancy are 
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general muscle hypotonia,  feeding difficulties and un- 
derweight due to poor  sucking and swallowing reflexes. 
Between the 2nd and 4th year of  life, obesity sets in as a 
consequence of  uncontrolled compulsive eating. Growth  
is characterised by moderate  intra-uterine and postnatal  
growth delay, lack of  a pubertal  growth spurt and short 
stature as an adult. Hypogenital ism and cryptorchidism 
are comm on  features in addition to delayed psychomo- 
tor development,  mental  retardation and behavioural  
problems with temper  tantrums. 
The link between the chromosomal  disorder and the 
clinical manifestations is unknown. Various hypotha-  
lamic centres are assumed to be involved and several 
lines of  evidence suggest that a growth hormone  defi- 
ciency ( G H D )  due to hypothalamic dysregulation may 
contribute to an abnormal  growth pattern,  decreased 
lean body mass, muscle hypotonia,  increased total body 
fat [16] and low energy expenditure [26]. 
Growth  hormone  (GH)  response to insulin, arginine, 
clonidine and dopa  are reported to be low-normal  or 
blunted [1, 4, 7, 8, 16, 28], as are sleep-induced G H  
secretion [9] and 24-h integrated G H  concentrations [1]. 
In contrast  to simple obesity, insulin-like growth factor 
( IGF)- I  [2, 8, 15, 16] and insulin-like growth factor 
binding protein-3 [16] were reported to be low or in the 
low-normal range. 
There is some evidence that G H  treatment may ac- 
celerate growth and reduce weight for height [1, 2, 15, 
16, 24, 29]. Short  stature, even though a distinct feature 
(average height of  an adult PWS male is 152 cm, of  a 
female 146 cm) [6], does not pose as much of  a problem 
for the children with PWS and their families, as do 
polyphagia and overweight, poor  physical and intellec- 
tual performance,  and the optimal enhancement  of  ed- 
ucational and physical performance.  We were therefore 
hoping for the fat-reducing and anabolic, muscle-in- 
creasing influence of  G H  to enhance strength and 
physical performance.  We expected it to have an equally 
positive effect on muscle hypotonia  and general ady- 
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namia and to improve well-being. The purpose of  this 
study is to provide an accurate documentat ion of  the 
G H  treatment-induced changes and to support  the as- 
sumed presence of a genuine G H D ,  secondary to a hy- 
pothalamic dysfunction. This paper  presents the results 
of  the 1st year of  treatment.  
Subjects and methods 
Subjects (Table 1) 
Twelve children with PWS (6 boys, 6 girls) with documented de- 
letion or uniparental disomy of chromosome 15. 
Treatment 
Administration of hGH (24 U/mZ/week) in daily subcutaneous 
injections for the duration of 1 year. No other treatment was ad- 
ministered, in particular no substitution of sex steroids in the older 
pubertal children. 
Methods 
Anthropometric measurements 
The anthropometric measurements were performed by the first 
author according to standard techniques [11, 21]. 
All auxological results are given as SDS, using the first Zurich 
Longitudinal Study as reference [21] with exception of arm span, 
hand and foot length, for which the standards of the Oosterwolde 
study [11] were used. 
All data were processed by GAS 3.0 of the Institute for Medical 
Informatics, IMI, Zurich, Switzerland. 
Due to the age-related variations in the syndrome's manifesta- 
tions, the patients were divided into three groups: 
1. Group 1: six prepubertal, obese children, aged between 3.8 and 
7.0 years 
2. Group 2: three young, not yet obese children, aged between 0.6 
and 4.1 years 
3. Group 3: three pubertal children (Tanner stage 2 and 3), aged 
between 9.2 and 14.6 years. 
Table 1 Study subjects 
Patient Sex Age at 
number beginning 
(years) 
Group 1 
1 F 3.7 
2 F 5.0 
3 F 6.7 
4 M 6.8 
5 F 7.0 
6 M 7.O 
Group 2 
7 M 1.5 
8 M 1.8 
9 M 4.1 
Group 3 
10 F 9.0 
11 M 13.5 
12 F 14.6 
Bone age Mother Father Mean target 
(Greulich-Pyle) height height height [21] 
at beginning (cm) (cm) SDS 
(years) 
2.5 167.0 184.0 0.7 
164.5 167.0 -0.9 
6.5 164.5 167.0 -0.9 
5.3 166.0 183.0 0.4 
5.8 160.0 178.0 -0.4 
7.8 163.0 172.0 -0.6 
0.8 152.0 165.0 -1.9 
1.3 171.0 173.0 0.1 
2.0 168.0 168.0 -0.5 
11.5 169.0 183.0 0.8 
14.5 162.0 174.0 -0.5 
12.5 155.5 170.0 -1.4 
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Body composition 
Body composition was determined by dual-energy X-ray 
absorptiometry (DEXA) (Hologic QDR-2000, Waltham, Mass., 
USA, Software version 7.10 B). 
Anaerobic perJbrmance (ergometer) 
Muscle endurance and peak power were measured by the Wingate 
anaerobic test (WANT), which is a 30-s cycling test at 'all-out' speed, 
against a constant braking force (Fleisch-Metabo mechanical ergo- 
meter, Switzerland, with pedal revolutions read continuously by a 
counter) [12]. The test was preceded by a 4-min warm up (pedalling 
at a mild pace, which yielded a heart rate of 110 130 beats/min), 
interspersed by several all-out sprinting trials of 2 3 s each. These 
trials were used for learning the sprinting task, as well as for deter- 
mining the braking force that would subsequently be used in the test. 
On the command 'start', the subject started pedalling at maximal 
speed. Encouragement was given throughout the 30-s period. Two 
performance indices were calculated: peak power (the highest me- 
chanical power at any 3-s period) and mean power (the power av- 
eraged over 30 s). These powers were calculated in Watts per 
kilogram body weight and as a percentage of normal values [3, 12]. 
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Fig. 1 Auxology values (SDS) of group 1 (3.8-7.0 years; n = 6; mean • 1 SD) during 1 year of treatment 
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Physical activity pattern (parents" opinion) 
Parents '  impression was obtained by means of a semistructured 
interview prior to the treatment, and after 6 and 12 months.  This 
interview consisted (1) of open-ended questions on the changes to 
which the parents gave an answer by freely reporting what they had 
noticed; and (2) of specific questions relating to physical activity, 
namely on the differences compared to siblings and other children, 
on the activity itself (kind of activity, favourite activity, endurance) 
and differences found compared to the pre-treatment situation. For  
example: when parents told in the interview about  their favourite 
family sport activity being the Sunday walk or an excursion on 
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bicycles, they were further asked about  how long and intensive this 
activity was and how the child behaved during this activity or 
whether it complained. 
Laboratory measurements 
Blood samples were taken between 8 a.m. and 9 a.m., after a 12-h 
overnight fast. IGF-I  was measured in sera after acid ethanol ex- 
traction as described [31]. Tests of significance were performed with 
One Sample Wilcoxon test, a P value of less than 0.05 was con- 
sidered significant. 
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skinfolds decreased as treatment progressed, both over 
the triceps (from 3.4 SD to -0.4 SD) and subscapularly 
(from 11.8 SD to 2.3 SD). Arm circumference dropped 
from 1.8 SD to 0.4 SD. In terms of SDS difference, the 
increase in hand length (from -1.5 SD to -0.4 SD), foot 
length (from -2.2 SD to -1.3 SD), arm span (from 
-1.6 SD to -0.5 SD) and sitting height (from -2.5 SD to 
-1 .4  SD) was similar to the increase in height. 
Group 2 (n = 3, age 0.6 to 4.1 years) (Fig. 2) 
Height increased from -2.4 SD to -1.2 SD. But in con- 
trast to the older children of group 1, these very young and 
initially underweight children showed an increase in 
weight for height from -2.0 SD to -0.9 SD. However, 
skinfolds decreased, both over the triceps (0.3 SD to -1.5 
SD) and subscapularly (from 2.4 SD to -0.6 SD). The 
other parameters changed similarly to those of group 1. 
Group 3 (n = 3, age 9.2 to 14.6 years) (Fig. 3) 
subscapularly from 16.3 SD to 10.3 SD) in the presence 
of an unchanged arm circumference (3.0 SD). 
Body composition 
Body composition measured by DEXA (Fig. 4) 
Only in older children (group 1 and 3) could body 
composition be determined by DEXA, due to the need 
for sedation in very young children. In one child of 
group 3, the second measurement could not be per- 
formed for technical reasons. 
In group 1, fat tissue dropped from an initial 43 % to 
29% (from 10.2 kg to 7.3 kg) after 12 months, which 
corresponds to a decrease of 35%, whereas fat free mass 
(FFM) increased from 57% to 71% (from 13.2 kg to 
16.5 kg), representing a 24% increase. In group 3, fat 
tissue dropped from 54% to 50% (from 33.6 kg to 
38.7 kg). FFM increased from 46% to 50% (from 
29.2 kg to 38.6 kg). 
The results of group 3 reflect the small size and hetero- 
geneity of this group, due to the major differences in 
height and particularly in weight and bone age. Height 
increased only moderately from -1.8 SD to -1.4 SD. 
Weight for height increased further from 6.6 SD to 7.1 
SD, but even in these patients, skinfolds decreased, al- 
though to a lower extent (triceps from 7.8 SD to 5.3 SD; 
Physical performance 
Anaerobic performance measured on the ergometer 
(Table 3) 
This test was performed with four children of group 1, 
all of them approx. 7 years of age at the beginning of the 
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treatment (age distribution 6.8-7.0 years) and with one 
child of group 3, since one child of group 3 was too 
handicapped and the other one too obese to perform this 
test. The other children were too short. 
Table 3 shows the results of the WANT. There was an 
increase in peak and mean power per kg body weight in 
group 1 from pre-treatment to 12 months later. The 
increase, whether expressed per kg body weight or as a 
percentage of a normal population, all showed an in- 
crease which nearly reached significance (P = 0.08- 
P = 0.05). 
Physical activity pattern." parents' opinion 
Parents, physiotherapists and paediatricians unani- 
mously reported an increase in physical activity and 
performance. At the same time, the children became 
more attentive and more lively, which made them more 
independent, more self-assured and less anxious. 
The improvement in physical performance was the 
most important therapy effect for the parents, even more 
than the loss of weight. As an example, a walk with the 
family of 3 h had been impossible before treatment and 
was now possible without the child complaining. Like- 
wise, the children became able to climb up the wall bars 
or the climbing pole. 
Serum concentrations of IGF-I (Fig. 5) 
Before treatment, the children of our study had lower 
IGF-I serum concentrations when compared to those of 
age-matched normal-weight children (SDS: -0.6 + 0.8, 
P = 0.03) [32]. During hGH treatment, IGF-I (SDS: 
2.0 + 1.4) rose to the supraphysiological range in the 
first 6 months and remained stable thereafter. 
Discussion 
GH treatment led to remarkable clinical and auxological 
changes in the prepubertal and initially obese children 
with PWS. All prepubertal children showed an impres- 
sive increase in growth velocity and a distinct catch-up 
growth. In terms of SDS difference, the increase in foot 
length, hand length and arm span was of the same order 
as the increase in height. One year into treatment, mean 
height was still below the age-related mean, but catch-up 
growth continued. 
All prepubertal children, who were obese before 
treatment, showed a distinct decrease in weight for 
height, BMI, skinfolds thickness and body fat measured 
by DEXA, but after the 12-month treatment period, not 
all body fat parameters had dropped to the normal 
range and body fat was still elevated. Subscapular fat 
was greater than over the triceps, both before and after 
the 12-month treatment. Fat distribution, in PWS typi- 
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Table 3 Wingate anaerobic test 
Group (n) 
l ( n  = 4) 
3(n - 1) 
Months Peak power Peak power Mean power Mean power 
per kg %norm per kg %norm 
0 
12 
0 
12 
3.36 • 0.63 57.52 • 7.12 3.05 • 0.47 58.9 • 8.4 
6.42 • 1.32 100.4 • 16.1 4.54 • 0.54 82.5 • 9.4 
3.9 41 2.6 39 
5.7 57 3.9 57 
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3.5 
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1.0 
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-0.5 
-1.0 
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IGF- I  
I 
- I 
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Months 
Fig. 5 IGF-I of all subjects (0.(~13.8 years; n = 12; mean • 1 SD) 
during 1 year of treatment 
cally concentrated on the trunk [20], is maintained even 
after 12 months of treatment. 
Estimates based on anthropometric measurements 
and DEXA measurements revealed a distinct increase in 
lean body mass (LBM), both in relative figures (%) as 
well as absolutely (kg). Arm circumference dropped 
much less than triceps skinfolds, suggesting that the 
LBM increase exceeded the normal growth-related in- 
crease that one would expect. 
The results of the anaerobic performance test con- 
firmed, at least in the older prepubertal children, that the 
increase in muscle mass was accompanied by an im- 
provement in physical performance. Parents reported 
that the children showed a higher physical activity and 
also much more enjoyed it, which is of particular inte- 
rest. GH treatment seems to bring about not only an 
increase in muscle mass and physical performance, but 
also to cause the children to be more active, which may, 
additionally to the direct effects of GH, also have a 
positive influence by increasing energy expenditure and 
muscle mass and decreasing body fat. 
In the very young children who were underweight at 
the beginning of treatment, an increase of weight for 
height was seen, almost exclusively due to an increase of 
LBM, since subcutaneous fat decreased. GH treatment 
in young and older children therefore seems to have the 
same effects with the exception of weight, probably be- 
cause, in very young children, muscle mass increase 
outweighs body fat decrease. 
The pubertal obese children showed a tendency for 
the same changes as the younger children, even though 
to a far lower extent. The small sample size and heter- 
ogeneity of the group as regards weight, height and bone 
age render conclusions difficult. In addition, all three 
patients had a non-substituted partial gonadotropin 
deficiency. Generally, only a moderate increase in height 
was observed, probably due to insufficient sex steroid 
levels and advanced bone age. Nevertheless the SDS 
increase in hand length, foot length and arm span was 
found to be of a similar order to the increase in body 
height. Weight for height rose further, but skinfolds 
decreased, even though to a lower extent than in the 
other groups. 
Treatment effects in terms of height, weight, and 
weight for height were in agreement with earlier publi- 
cations [2, 15, 16, 24, 29]. It was not possible to compare 
effects on growth of the extremities, changes in physical 
performance and physical activity, because to our 
knowledge, these effects have not been studied so far. 
As other authors, we found some evidence in favour 
of a hypothalamic G H D  in PWS: pre-treatment IGF-I 
was significantly lower than in normal-weight children, 
but not as low as expected in GHD. This may be ex- 
plained by the fact that IGF-I is related to food intake 
and is increased in normal obese children [18, 30]. 
Moderately reduced IGF-I levels in PWS therefore 
constitute an argument in favour of GHD. Furthermore, 
increased total body fat as well as decreased absolute 
F F M  is a typical finding in GHD [17, 25, 27]. By con- 
trast, in simple obesity, increased total body fat is found 
together with increased absolute F F M  [10] which is 
probably due to the fact that it simply needs more 
muscle mass to carry around a heavy body. Therefore, 
we tried to compare absolute FFM measured by DEXA 
with normal data. So far, however, there are very few 
reference values for the absolute F F M  in children. 
Lazarus et al. [13] have published standards based on 
age quintiles and sex. These tables contain age and the 
corresponding mean height. Since PWS children are 
below average in height, we plotted their data against 
height in the table, and not against the age. By inter- 
polating height data we calculated the corresponding 
expected F F M  in kilograms and compared it to the real 
absolute F F M  in kg of the relevant child (see Table 2). 
At the beginning of the treatment, however, the children 
of the study were too young and too small for the ref- 
erence data. Therefore, this comparison could only be 
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made 6 and 12 months into treatment and only in six out 
of  nine children. Absolute F F M  was found to be lower 
than expected after 6, but also after 12 months. The 
mean difference between real and expected absolute 
muscle mass was -2 .4  kg after 6 months and -1.6 kg 
after 12 months. Formally, it was not possible to prove a 
reduced F F M  before treatment due to the lack of  
normal values for small children, but extrapolation of 6- 
and 12-month data, as well as the assessment of  
anthropometric data may allow the conclusion that 
FFM  was also reduced before treatment, as it is the case 
in GHD.  
GH treatment in PWS leads to marked changes. 
Weight for height decreased in overweight children and 
increased in underweight children. Body fat decreased 
and an increase in growth velocity and height, as well as 
in growth of hands and feet was seen. With the increase 
in muscle tissue, physical performance improved. Par- 
ents, care personnel and physiotherapists were highly 
pleased about the higher physical activity and report 
that the children now much more enjoy physical 
activity. 
Age-related evaluation of  our data suggests that if 
GH treatment is taken into consideration, it should be 
instituted as early as possible, in any case before pu- 
bertal development sets in. In pubertal children, treat- 
ment-induced changes were poor, which may partly be 
attributed to the non-substitution of  the partial gonad- 
otropin deficiency. Based on further evidence of  G H D  in 
PWS and because of  the supraphysiological IGF- I  levels 
under treatment, it may be concluded that the admin- 
istrated, moderately supraphysiological GH dosage was 
too high. Further studies with physiological substitution 
dosage should follow. 
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